https://www.selleckchem.com/pr....oducts/shp099-dihydr
f ~75% of CR programs, with others ceasing initiation of new patients, reducing components delivered, and/or changing of mode delivery with little opportunity for planning and training.- There is also significant psychosocial and economic impact on CR providers.- Alternative CR model (e.g., home-based, virtual) reimbursement advocacy is needed, to ensure safe, accessible secondary prevention delivery. QTc prolongation is an adverse effect of COVID-19 therapies. The use of a handheld device in this scenario has not been ad
Beğen
Yorum Yap
Paylaş
